New biotech business model will 'address pharma's research outsourcing trend'
This article was originally published in Scrip
Executive Summary
The German biotech company 4SC has decided to transfer most of its early-stage research activities to a 100%-owned subsidiary. "We are convinced this new business model addresses the current trends in the pharma industry to collaborate more in early stage R&D," Dr Ulrich Dauer, CEO of 4SC, told Scrip.